105 related articles for article (PubMed ID: 25374407)
1. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.
Piatek CI; Raja GL; Ji L; Gitlitz BJ; Dorff TB; Quinn DI; Hu J; El-Khoueiry AB; Pham HQ; Roman L; Garcia AA
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1227-34. PubMed ID: 25374407
[TBL] [Abstract][Full Text] [Related]
2. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
3. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
[TBL] [Abstract][Full Text] [Related]
5. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
Lê LH; Moore MJ; Siu LL; Oza AM; MacLean M; Fisher B; Chaudhary A; de Alwis DP; Slapak C; Seymour L
Cancer Chemother Pharmacol; 2005 Aug; 56(2):154-60. PubMed ID: 15809877
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
[TBL] [Abstract][Full Text] [Related]
11. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
[TBL] [Abstract][Full Text] [Related]
12. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
[TBL] [Abstract][Full Text] [Related]
16. A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors.
Kakolyris S; Kouroussis C; Koukourakis M; Mavroudis D; Malas K; Vardakis N; Bozionelou V; Kalbakis K; Georgoulias V
Oncology; 2002; 63(3):213-8. PubMed ID: 12381899
[TBL] [Abstract][Full Text] [Related]
17. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
Delva R; Pienkowski T; Tubiana N; Vanhoefer U; Longerey B; Douville I
Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
[TBL] [Abstract][Full Text] [Related]
18. Continuous-infusion vinorelbine for the treatment of advanced non-small-cell lung cancer: a phase I/II study.
Carabante-Ocón F; Cobo-Dols M; Benavides-Orgaz M; Gil-Calle S; Alés-Díaz I; Bretón-García JJ; Villar-Chamorro E; Montesa-Pino A; Alcalde-García J; Gutiérrez-Calderón V
Clin Lung Cancer; 2005 Sep; 7(2):121-6. PubMed ID: 16179099
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK
Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]